Abera Bioscience

Abera Bioscience P/B

The P/B (Price-to-Book Ratio) of Abera Bioscience (ABERA.SL) as of Oct 15, 2026 is 6.20. In the previous year, P/B (Price-to-Book Ratio) was 13.81 — a change of -55.12% (lower).

P/B

6.20

YoY

-55.12%

Last updated:

P/B (Price-to-Book Ratio) of Abera Bioscience is 2025 6.20 . P/B (Price-to-Book Ratio) of Abera Bioscience was 2024 13.81 . It decreases by -55.12% lower compared to the previous year.

The Abera Bioscience P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2018
301.06 SEK
Jan 1, 2019
29.36 SEK
Jan 1, 2020
279.25 SEK
Jan 1, 2021
4.10 SEK
Jan 1, 2022
7.12 SEK
Jan 1, 2023
21.14 SEK
Jan 1, 2024
13.81 SEK
Jan 1, 2025
6.20 SEK
The Abera Bioscience P/B history
YEARP/BYoY
6.20-55.12%
13.81-34.67%
21.14+196.71%
7.12+73.74%
4.10-98.53%
279.25+851.17%
29.36-90.25%
301.06+663.48%
39.43—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Abera Bioscience Stock analysis

What does Abera Bioscience do? Abera Bioscience AB is a biotechnology company based in Uppsala, Sweden, operating within the healthcare sector. The company focuses on the research and development of pharmaceutical products, particularly in the field of vaccine development. It utilizes a proprietary vaccine delivery platform to advance vaccine candidates toward late pre-clinical or early clinical stages. Abera Bioscience aims to identify licensing partners for further development of its vaccine candidates. The company's technology is primarily applied in the development of vaccines targeting pneumococci and immunooncology. Abera Bioscience has a small operational footprint, employing five full-time staff members. It completed its initial public offering (IPO) on February 24, 2021, and is listed under the ticker ABERA.SL with ISIN SE0015245097. The company's headquarters are located in Uppsala, and it operates primarily within the Nordic market. Its website is https://aberabio.com/. The company's activities are centered on advancing vaccine candidates through its platform technology, with an emphasis on strategic partnerships for subsequent development phases. Abera Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Abera Bioscience stock

P/B (Price-to-Book Ratio) of Abera Bioscience is 6.20 in 2025.

P/B (Price-to-Book Ratio) of Abera Bioscience changed from 13.81 to 6.20, representing a -55.12% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Abera Bioscience since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Abera Bioscience with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Abera Bioscience

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Abera Bioscience